Previous reports have shown that the expression of soluble immune checkpoint molecules in the plasma reflects heterogeneity across tumors, whereas the expression of PD-L1 in tumors is heterogeneous, not only within a single tumor site but also between various tumor sites [31,32]. This evidence concerns the gene CD274 and neoplasm.